DJ Grant, A Manichaikul, AJ Alberg, EV Bandera, J Barnholtz-Sloan, M Bondy, ML Cote, E Funkhouser, PG Moorman, LC Peres, ES Peters, AG Schwartz, PD Terry, X-Q Wang, TO Keku, C Hoyo, A Berchuck, DP Sandler, JA Taylor, KM O'Brien, DR Velez Edwards, TL Edwards, A Beeghly-Fadiel, N Wentzensen, CL Pearce, AH Wu, AS Whittemore, V McGuire, W Sieh, JH Rothstein, F Modugno, R Ness, K Moysich, MA Rossing, JA Doherty, TA Sellers, JB Permuth-Way, AN Monteiro, DA Levine, VW Setiawan, CA Haiman, L LeMarchand, LR Wilkens, BY Karlan, U Menon, S Ramus, S Gayther, A Gentry-Maharaj, KL Terry, DW Cramer, EL Goode, MC Larson, SH Kaufmann, R Cannioto, K Odunsi, JL Etter, R-Y Huang, MQ Bernardini, AA Tone, T May, MT Goodman, PJ Thompson, ME Carney, SS Tworoger, EM Poole, D Lambrechts, I Vergote, A Vanderstichele, E Van Nieuwenhuysen, H Anton-Culver, A Ziogas, JD Brenton, L Bjorge, HB Salvensen, LA Kiemeney, LFAG Massuger, T Pejovic, A Bruegl, M Moffitt, L Cook, ND Le, A Brooks-Wilson, LE Kelemen, PDP Pharoah, H Song, I Campbell, D Eccles, A DeFazio, CJ Kennedy, JM Schildkraut
An association between genetic variants in the vitamin D receptor (VDR) gene and epithelial ovarian cancer (EOC) was previously reported in women of African ancestry (AA). We sought to examine associations between genetic variants in VDR and additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). Genotyping was performed using the custom-designed 533,631 SNP Illumina OncoArray with imputation to the 1,000 Genomes Phase 3 v5 reference set in 755 EOC cases, including 537 high-grade serous (HGSOC), and 1,235 controls. All subjects are of African ancestry (AA). Logistic regression was performed to estimate odds ratios (OR) and 95% confidence intervals (CI). We further evaluated statistical significance of selected SNPs using the Bayesian False Discovery Probability (BFDP). A significant association with EOC was identified in the UGT2A1/2 region for the SNP rs10017134 (per allele OR = 1.4, 95% CI = 1.2-1.7, P = 1.2 × 10-6 , BFDP = 0.02); and an association with HGSOC was identified in the EGFR region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = 1.6-3.4, P = 1.6 × 10-5 , BFDP = 0.29) and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% CI = 1.2-1.7, P = 2.3 × 10-5 , BFDP = 0.23). Genetic variants in the EGFR and UGT2A1/2 may increase susceptibility of EOC in AA women. Future studies to validate these findings are warranted. Alterations in EGFR and UGT2A1/2 could perturb enzyme efficacy, proliferation in ovaries, impact and mark susceptibility to EOC.